Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Big pharma joins UK government in Alzheimer's research funding boost

This article was originally published in Scrip

Executive Summary

Biogen, GlaxoSmithKline, Johnson & Johnson, Lilly and Pfizer have all committed in principle to investing, alongside the charity Alzheimer's Research UK and the UK government, in a $100m Dementia Discovery Fund announced by the UK health secretary Jeremy Hunt at the World Health Organization’s First Ministerial Conference on Global Action Against Dementia on 17 March. The UK government has been working with JP Morgan to structure the Dementia Discovery Fund as an innovative method for financing dementia research. It will be structured as a typical venture capital fund, but will be the first to focus solely on dementia research. The idea is to bring together the combined expertise of government, financial, industry and charity partners to develop pioneering new drugs to treat the condition. The money committed by investors includes the £15m that the UK government announced for the fund in autumn 2014, plus $25m (about £17m) from GlaxoSmithKline, $10m from Johnson & Johnson and further undisclosed commitments from the other companies. There will be an opportunity for additional interested investors to participate in the fund at a later stage.

You may also be interested in...



Finance Watch: Dementia Discovery Fund Exceeds Fundraising Goal By $150m

Private Company Edition: The Dementia Discovery Fund started in 2015 with plans to raise $200m to fund early-stage development of disease-modifying drugs, but recently closed its fundraising with $350m in commitments. Also, Kaleido's $101m Series C is among three recent $100m-plus rounds.

Pfizer And Shionogi Form Vanguard In New Subscription Assault On Antibiotic Resistance

Two antibiotics from Pfizer and Shionogi are to be rolled out by the UK’s NHS in a pioneering subscription deal that hopes to encourage antibiotic R&D by delinking payment from volume of use.

Five Late-Breaking Studies To Look Out For At ASCO

Ahead of the American Society of Clinical Oncology meeting in early June, analysts at Biomedtracker have highlighted select high-impact late-breaking abstracts that are due to presented, including therapies from AbbVie, Gilead Sciences, Pfizer, Takeda, Amgen, AstraZeneca and Daiichi Sankyo.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC028136

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel